Travere research chief sells 209K shares after exercise

Travere Therapeutics’ Chief Research Officer exercised options and sold over 200,000 shares in mid-September 2026 under a Rule 10b5-1 trading plan.

Rhea-AI Filing Summary

Travere Therapeutics, Inc. (TVTX) reported that its Chief Research Officer, William E. Rote, exercised employee stock options for a total of 191,500 shares of common stock on September 15-16, 2026, at exercise prices including $15.46, $17.96, $25.25 and $26.88 per share. Over the same two days he sold an aggregate of 209,048 shares of common stock in open-market transactions at weighted average prices generally in the low-to-mid $60s per share. The sales were made pursuant to a written trading plan adopted on June 16, 2026, that meets the requirements of Rule 10b5-1(c), and the stock options exercised were reported as fully vested and exercisable.

Insider Trade Summary 10b5-1

Exercise and sale activity reported; no spread calculated

Exercise and Sale 16 txns

Insider ROTE WILLIAM E.

Role Chief Research Officer

Sold 209,048 shs ($13.14M)

Approx. gross sale proceeds $13.14M

Approx. exercise cost $4.10M

Type	Security	Shares	Price	Value
Exercise	Employee stock option (right to buy) F8	350	$0.00	$0.00
Exercise	Employee stock option (right to buy) F8	55,000	$0.00	$0.00
Exercise	Employee stock option (right to buy) F8	57,500	$0.00	$0.00
Exercise	Common Stock	350	$17.96	$6K
Exercise	Common Stock	55,000	$15.46	$850K
Exercise	Common Stock	57,500	$26.88	$1.55M
Sale	Common Stock F2, F6	65,104	$63.1205	$4.11M
Sale	Common Stock F2, F7	47,746	$63.6126	$3.04M
Exercise	Employee stock option (right to buy) F8	39,000	$0.00	$0.00
Exercise	Employee stock option (right to buy) F8	39,650	$0.00	$0.00
Exercise	Common Stock F1	39,000	$25.25	$985K
Exercise	Common Stock	39,650	$17.96	$712K
Sale	Common Stock F2, F3	63,907	$61.994	$3.96M
Sale	Common Stock F2, F4	29,021	$62.6552	$1.82M
Sale	Common Stock F2, F5	3,000	$63.6508	$191K
Sale	Common Stock F2	270	$65.31	$18K

Holdings After Transaction: Employee stock option (right to buy) — 0 contracts (Direct); Common Stock — 98,197 shares (Direct)

Footnotes (8)

1. F1. Includes 271 shares acquired under the Issuer's 2017 Employee Stock Purchase Plan on May 29, 2026.
2. F2. This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.
3. F3. The weighted average sale price for the transaction reported was $61.994, and the range of prices were between $61.405 and $62.40. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
4. F4. The weighted average sale price for the transaction reported was $62.6552 and the range of prices were between $62.41 and $63.32. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
5. F5. The weighted average sale price for the transaction reported was $63.6508, and the range of prices were between $63.49 and $63.99. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided
6. F6. The weighted average sale price for the transaction reported was $63.1205, and the range of prices were between $62.47 and $63.4650. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
7. F7. The weighted average sale price for the transaction reported was $63.6126, and the range of prices were between $63.47 and $63.96. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
8. F8. The stock option is fully vested and exercisable.

Key Figures

Options exercised: 191,500 shares Shares sold: 209,048 shares Exercise price: $25.25 per share +5 more

8 metrics

Options exercised 191,500 shares Common stock underlying employee stock options exercised on September 15-16, 2026

Shares sold 209,048 shares Open-market sales of Travere Therapeutics common stock on September 15-16, 2026

Exercise price $25.25 per share Stock options exercised for 39,000 shares on September 15, 2026

Exercise price $15.46 per share Stock options exercised for 55,000 shares on September 16, 2026

Exercise price $26.88 per share Stock options exercised for 57,500 shares on September 16, 2026

Weighted average sale price $61.994 per share Sale of 63,907 shares on September 15, 2026; price range $61.405–$62.40

Weighted average sale price $63.1205 per share Sale of 65,104 shares on September 16, 2026; price range $62.47–$63.4650

Weighted average sale price $63.6126 per share Sale of 47,746 shares on September 16, 2026; price range $63.47–$63.96

Key Terms

Rule 10b5-1(c), Employee stock option (right to buy), weighted average sale price, 2017 Employee Stock Purchase Plan, +1 more

5 terms

Rule 10b5-1(c) regulatory

"plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c)"

Rule 10b5-1(c) is an SEC guideline that lets company insiders set up a written, pre-planned schedule to buy or sell their company stock when they are not in possession of material, nonpublic information. For investors, it matters because such plans can reduce the appearance of insider trading by separating decisions from inside knowledge—like putting your trades on autopilot—while also requiring scrutiny since pre-planned trades can still affect market confidence and share value.

Employee stock option (right to buy) financial

"security title is Employee stock option (right to buy) with common stock underlying"

weighted average sale price financial

"The weighted average sale price for the transaction reported was $61.994"

2017 Employee Stock Purchase Plan financial

"Includes 271 shares acquired under the Issuer's 2017 Employee Stock Purchase Plan"

fully vested and exercisable financial

"The stock option is fully vested and exercisable."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did TVTX report for its Chief Research Officer?

Travere Therapeutics reported that Chief Research Officer William E. Rote exercised employee stock options for 191,500 shares of common stock and sold 209,048 shares of common stock in open-market transactions on September 15-16, 2026.

How many Travere Therapeutics (TVTX) shares did William E. Rote sell and at what prices?

William E. Rote sold a total of 209,048 shares of Travere Therapeutics common stock on September 15-16, 2026 at weighted average sale prices including $61.994, $62.6552, $63.6508, $63.1205 and $63.6126 per share, within disclosed intraday price ranges.

Were the recent TVTX insider sales made under a Rule 10b5-1 trading plan?

Yes. The filing states that the sales were made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) under the Securities Exchange Act of 1934, and the document-level Rule 10b5-1 checkbox is affirmed.

What stock options did the TVTX Chief Research Officer exercise in September 2026?

On September 15-16, 2026, William E. Rote exercised employee stock options covering 191,500 shares of Travere common stock at exercise prices of $15.46, $17.96, $25.25 and $26.88 per share, with the options reported as fully vested and exercisable.

Did any of the reported TVTX transactions involve shares from the Employee Stock Purchase Plan?

Yes. One line item notes that it includes 271 shares acquired under Travere Therapeutics’ 2017 Employee Stock Purchase Plan on May 29, 2026, which are part of the direct common stock holdings referenced in that transaction row.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/17/2026 - 09:36 PM Accepted by SEC EDGAR 09/17/2026 - 09:35 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ROTE WILLIAM E.

(Last) (First) (Middle)

C/O TRAVERE THERAPEUTICS, INC.

3611 VALLEY CENTRE DRIVE, STE 300

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Travere Therapeutics, Inc. [ TVTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Research Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/15/2026		M		39,000	A	$25.25	154,745(1)	D
Common Stock	09/15/2026		M		39,650	A	$17.96	194,395	D
Common Stock	09/15/2026		S(2)		63,907	D	$61.994(3)	130,488	D
Common Stock	09/15/2026		S(2)		29,021	D	$62.6552(4)	101,467	D
Common Stock	09/15/2026		S(2)		3,000	D	$63.6508(5)	98,467	D
Common Stock	09/15/2026		S(2)		270	D	$65.31	98,197	D
Common Stock	09/16/2026		M		350	A	$17.96	98,547	D
Common Stock	09/16/2026		M		55,000	A	$15.46	153,547	D
Common Stock	09/16/2026		M		57,500	A	$26.88	211,047	D
Common Stock	09/16/2026		S(2)		65,104	D	$63.1205(6)	145,943	D
Common Stock	09/16/2026		S(2)		47,746	D	$63.6126(7)	98,197	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee stock option (right to buy)	$25.25	09/15/2026		M			39,000	(8)	05/10/2028	Common Stock	39,000	$0	0	D
Employee stock option (right to buy)	$17.96	09/15/2026		M			39,650	(8)	05/09/2029	Common Stock	39,650	$0	350	D
Employee stock option (right to buy)	$17.96	09/16/2026		M			350	(8)	05/09/2029	Common Stock	350	$0	0	D
Employee stock option (right to buy)	$15.46	09/16/2026		M			55,000	(8)	01/31/2030	Common Stock	55,000	$0	0	D
Employee stock option (right to buy)	$26.88	09/16/2026		M			57,500	(8)	01/21/2031	Common Stock	57,500	$0	0	D

Explanation of Responses:

1. Includes 271 shares acquired under the Issuer's 2017 Employee Stock Purchase Plan on May 29, 2026.

2. This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.

3. The weighted average sale price for the transaction reported was $61.994, and the range of prices were between $61.405 and $62.40. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

4. The weighted average sale price for the transaction reported was $62.6552 and the range of prices were between $62.41 and $63.32. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

5. The weighted average sale price for the transaction reported was $63.6508, and the range of prices were between $63.49 and $63.99. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided

6. The weighted average sale price for the transaction reported was $63.1205, and the range of prices were between $62.47 and $63.4650. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

7. The weighted average sale price for the transaction reported was $63.6126, and the range of prices were between $63.47 and $63.96. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

8. The stock option is fully vested and exercisable.

	/s/ Elizabeth E. Reed, Attorney-in-Fact	09/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)